News

24 03, 2020

COVID-19 Information for Prostate Cancer Patients

2020-03-24T09:30:41-07:00March 24th, 2020|

Many who have been affected by prostate cancer, or whose loved ones have been affected by prostate cancer, might be wondering if special precautions need to be taken with the coronavirus pandemic unfolding. We have always believed that evidence out of science and research are the best tools for solving patients’ problems, whether that’s cancer or public health emergencies. As such, we will do our best to use science to provide information and a steady hand in this tumultuous situation. Scientists know that the coronavirus (aka COVID-19 COrona VIrus Disease 2019) can affect your immune system, although we are still learning more. Based on recent data as reported in the journal The Lancet, it appears that the virus hits the immune system early [...]

17 03, 2020

California HIFU is the Right Choice for Prostate Cancer Treatment

2020-03-17T10:44:59-07:00March 17th, 2020|

For the past five years, Chris Lockheed’s PSA numbers had been going up. Then, when a biopsy revealed that he had two tumors on his prostate. Chris started doing research into what kind of options for treatment were available to him. When a radiation specialist in Rohnert Park told him about Dr. Michael Lazar and the HIFU procedure, he did more homework. Dr. Michael Lazar, 4 time board certified urologist, who has practiced in Santa Rosa for 36 years, investigated and became an early user of a new technology for treatment of prostate cancer called high intensity focused ultrasound, or HIFU. This exciting non-invasive technology uses ultrasound energy to create heat. This heat is precisely aimed at the cancerous portions of the gland to [...]

10 03, 2020

Pilot study repurposes antidepressant to fight prostate cancer

2020-03-10T12:53:09-07:00March 10th, 2020|

An antidepressant in use for decades, repurposed to fight prostate cancer, shows promise in helping patients whose disease has returned following surgery or radiation, a pilot study at USC shows. The drug -- an MAO inhibitor called phenelzine -- represents a potential new treatment direction with fewer side effects for men with recurrent prostate cancer, researchers said. "To our knowledge, this study is the first clinical trial of an MAO inhibitor in cancer patients," said senior author Jean Shih, a University Professor in USC's School of Pharmacy who has studied the enzyme MAO, or monoamine oxidase, for four decades. The research appears in the journal Prostate Cancer and Prostatic Diseases. "If our findings are confirmed, this could be part of a new avenue [...]

3 03, 2020

Understanding when to start prostate cancer screening

2020-03-03T12:14:39-08:00March 3rd, 2020|

According to the latest research on prostate cancer prevention, it's important to be proactive and consult with a doctor to establish a prostate cancer screening schedule. The choice of screening options should make sense and take into consideration the personal risk factors and family history. Exactly when screening starts depends on a number of considerations, primarily based on statistics of prostate cancer and how it occurs among different population groups. Some important considerations include; Family history of prostate, ovarian, breast, colon, or pancreatic cancers among male and female relatives African ancestry Age Where a person lives Watch for These Signs More often than not, there are not fast and true warning signs for prostate cancer. That is because, an active prostate tumor usually [...]

24 02, 2020

Diabetes can affect prostate cancer prognosis

2020-02-24T11:37:44-08:00February 24th, 2020|

Men with type 2 diabetes are less likely to develop prostate cancer than patients without diabetes. However, the mortality rate is higher. Researchers were able to show that in the affected individuals the androgen receptor and the mitogenic forms of the insulin receptor were more strongly expressed. This could explain why patients with diabetes have a poorer prognosis for prostate cancer. Men with type 2 diabetes are less likely to develop prostate cancer than patients without diabetes. However, the mortality rate is higher. Researchers were able to show that in the affected individuals the androgen receptor and the mitogenic forms of the insulin receptor were more strongly expressed. This could explain why patients with diabetes have a poorer prognosis for prostate cancer. Prostate cancer [...]

18 02, 2020

Study examines prostate cancer treatment decisions

2020-02-18T10:25:52-08:00February 18th, 2020|

5-year study examines common prostate cancer treatment options (See new HIFU study results at bottom of this article.) A five-year follow-up study of more than 2,000 U.S. men who received prostate cancer treatment is creating a road map for future patients regarding long-term bowel, bladder and sexual function in order to clarify expectations and enable men to make informed choices about care. The CEASAR (Comparative Effectiveness Analysis of Surgery and Radiation for Localized Prostate Cancer) study, coordinated by Vanderbilt University Medical Center, is a multi-site research study conducting long-term followup on men who were diagnosed with localized prostate cancer between 2011 and 2012. The five-year results published in JAMA, with lead author Karen Hoffman, MD, MPH, from MD Anderson, provide evidence on outcomes with [...]

10 02, 2020

HIFU for prostate cancer shows excellent results in new study

2020-02-10T14:04:05-08:00February 10th, 2020|

Kia Michel, MD The 12th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer in Washington, D.C. featured Dr. Kia Michel, of Beverly Hills, Calif., who spoke on the outstanding data on focal HIFU outcomes for localized prostate cancer. Dr. Michel presented a poster on near-term HIFU outcomes based on his experience treating men with localized prostate cancer with the Sonablate. He presented that 78 men with prostate cancer underwent HIFU and were tracked post-treatment and re-biopsied at 12 months. He concluded that there was excellent disease control after HIFU ablation and most men were able to retain full urinary continence and erectile function levels equal to those pre-HIFU treatment. “I feel like it is important to report on [...]

4 02, 2020

Study reveals that being active has significant impact on prostate cancer risk

2020-02-04T13:01:18-08:00February 4th, 2020|

Prostate cancer is the number one cancer risk for men, as well as the No. 2 cancer killer behind lung cancer in the US, yet we still don't know all of its causes. The largest ever study to use genetics as a measurement for physical activity to look at its effect on prostate cancer, reveals that being more active reduces the risk of prostate cancer. Over 140,000 men were included in the study, of which, 80,000 had prostate cancer. This new study, published in the International Journal of Epidemiology in December, was led by the University of Bristol and co-funded by World Cancer Research Fund (WCRF) and Cancer Research UK (CRUK). It found that people with the variation in their DNA sequence that [...]

27 01, 2020

Benefits of HIFU technology revealed in 3 studies and reports

2020-01-27T13:26:59-08:00January 27th, 2020|

Three articles have appeared in press since June 2018 based on clinical trials undertaken in the U.K., that highlight the medium to long-term durability of Sonablate treatments in the control of prostate cancer when used in the partial gland ablation setting.1,2,3  Across the three articles and a total of more than 1,800 men, salvage free survival (no need for a whole gland or systemic treatment) was greater than 90% out as far as 60 months.  This excellent disease control was accompanied by a pad-free incontinence rate of greater than 98% and maintenance of erectile function in more than 80% of men. An additional article based on Canadian experience produced roughly similar results. 14 Dr. Mark Carol, CEO of SonaCare Medical writes,“While few will [...]

10 12, 2019

Immunotherapy may add years for prostate cancer patients

2019-12-10T09:21:43-08:00December 10th, 2019|

Some men with advanced prostate cancer who have exhausted all other treatment options could live for two years or more on immunotherapy, a major clinical trial has shown. Researchers found that a small proportion of men were 'super responders' and were alive and well even after the trial had ended despite having had a very poor prognosis before treatment. The study found that one in 20 men with end-stage prostate cancer responded to the immunotherapy pembrolizumab -- but although the number who benefited was small, these patients sometimes gained years of extra life. The most dramatic responses came in patients whose tumors had mutations in genes involved in repairing DNA, and the researchers are investigating whether this group might especially benefit from immunotherapy. [...]